The prevalence of osteoarthritis (OA) is rising in Canada, largely due to an ageing population and higher obesity rates. Viscosupplementation - direct injection of hyaluronic acid into the joints - has gained popularity as a minimally invasive option to relieve OA pain and possibly delay the need for more intensive treatments such as knee replacement surgery. As a result, Canada’s viscosupplementation market is projected to grow at a compound annual growth rate (CAGR) of over 7.5% from 2023 to 2033, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, Canada Viscosupplementation Market Share, reveals that Canada’s viscosupplementation market is projected to grow from $30m in 2023 to $70.3m in 2033.
The demand for viscosupplementation in Canada is also influenced by individuals' desire to maintain an active lifestyle even with OA. The knee is the most common site for treatment, although viscosupplementation is also performed on other joints, including the hip, shoulder, and ankle. Patients often prefer three- and five-injection treatment cycles due to their greater effect in pain relief, despite the associated higher costs.
Despite its growth, the viscosupplementation market faces challenges. Recent studies have questioned the effectiveness of hyaluronic acid injections in providing sustained pain relief, especially for knee OA. This has led to reduced doctor recommendations, which may discourage some patients from pursuing the treatment. Additionally, potential side effects following injections and limited clinical evidence supporting long-term benefits present barriers to the broader adoption of viscosupplementation.
Overall, while viscosupplementation remains a valuable option for OA patients looking to avoid surgery, the market’s growth is balanced by ongoing clinical debate and public perception.
These factors may shape future demand, making the ongoing research and advancements in treatment efficacy important for the Canadian viscosupplementation market's sustained expansion.
"Canada viscosupplementation market set to grow at over 7.5% CAGR through 2033" was originally created and published by Medical Device Network , a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.